Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 77

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 77
---
 Agreement if the Closing shall not have occurred on or before an outside date, which can be extended by mutual agreement. The original outside date included in the Merger Agreement was xv January31, 2024, and has been extended to April30, 2025 and further to June30, 2025, August31, 2025 and October31, 2025 thereafter by amendments. The Merger Agreement also provides that NLS shall pay to Kadimastem a termination fee of $10,000,000 plus the NLS Operating Expenses (as defined in the Merger Agreement), up to a maximum of $250,000 per month beginning July 28, 2024, and Transaction Expenses (as defined in the Merger Agreement) if NLS terminates the Merger Agreement prior to obtaining the Parent Requisite Vote (as defined in the Merger Agreement) to enter into a definitive agreement providing for a Parent Superior Proposal (as defined in the Merger Agreement) in accordance with the terms of the Merger Agreement. Further, the NLS Board may, following the termination of the Merger Agreement, elect to, among other things, attempt to complete another strategic transaction similar to the Merger, attempt to sell or otherwise dispose of certain assets of NLS or continue to operate the business of NLS. Q.When do you expect the Merger to be completed? The Closing is expected to take place (i) no later than the second business day following the satisfaction or waiver of the conditions described under the section titled “ Conditions to the Consummation of the Merger” beginning on page 159 of this proxy statement/prospectus, or (ii) on such other date as agreed to by the parties to the Merger Agreement in writing, in each case, subject to the satisfaction or waiver of the closing conditions. The Merger Agreement may be terminated by NLS and/or Kadimastem if the Closing has not occurred by October31, 2025. NLS and Kadimastem anticipate that the consummation of the Merger will occur in the third quarter of 2025. However, because the Merger is subject to a number of conditions, neither NLS nor Kadimastem can predict exactly when the Closing will occur or if it will occur at all. For a description of the conditions to the completion of the Merger, see the section titled “ Conditions to the Consummation of the Merger” beginning on page 159 of this proxy statement/prospectus. Q